Calithera Announces First Patient Dosed in a Phase I Study of CB-1158, the First-in-Class Inhibitor of the Immuno-Oncology Target Arginase
September 15, 2016 07:45 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
Calithera Biosciences Announces CB-839 Clinical Data Selected for Oral Presentation at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
September 07, 2016 08:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the discovering and developing novel...
Calithera Biosciences to Present at Two Healthcare Conferences in September
August 31, 2016 09:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences Appoints Suzy Jones to Board of Directors
August 10, 2016 16:06 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel...
Calithera Biosciences Reports Second Quarter 2016 Financial Results and Recent Highlights
August 09, 2016 16:06 ET
|
Calithera Biosciences, Inc.
Two novel agents that modulate tumor and immune cell metabolism in clinical developmentCalithera to host conference call today at 4:30pm ET SOUTH SAN FRANCISCO, Calif., Aug. 09, 2016 (GLOBE...
Calithera Announces Enrollment of First Patient in CB-839 in Combination with Checkpoint Modulator
August 04, 2016 08:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
Calithera Biosciences to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
August 02, 2016 09:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences Announces FDA Acceptance of Investigational New Drug Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune Metabolic Checkpoint
July 25, 2016 08:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences Reports CB-839 Phase I Solid Tumor Combination Data at the American Society of Clinical Oncology Annual Meeting
June 06, 2016 07:30 ET
|
Calithera Biosciences, Inc.
Future development to focus on renal cell carcinoma and triple negative breast cancerCalithera to host investor webcast on June 6, 2015 at 6:30 p.m. CT SOUTH SAN FRANCISCO, Calif., June 06, 2016 ...
Calithera Biosciences Reports First Quarter 2016 Financial Results and Recent Highlights
May 10, 2016 16:06 ET
|
Calithera Biosciences, Inc.
- CB-839 Phase 1b Clinical Data to be Presented at ASCO 2016- Key clinical leadership expansion- Calithera to Host Conference Call Today at 4:30pm Eastern TimeSOUTH SAN FRANCISCO, Calif.,...